ASK REDCHAT ANYTHING ABOUT NEUROGENE INC.
Neurogene Inc. (NASDAQ: NGNE)
Listen to this Section
$39.59
-0.0400
(
-0.10% )
0.0K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| NGN-401DetailsRare genetic disease, Rett syndrome |
Phase 1/2 |
| NGN-101DetailsRare genetic disease, Batten Disease |
Phase 1/2 |
Market Data
|
| Open |
$39.59 |
| Previous Close |
$39.63 |
| Volume |
0.0K |
| Market Cap |
$790.63M |
| Day Range |
$37.78 - $39.83 |
| 52 Week Range |
$15.93 - $43.66 |
| Shares Outstanding |
19.95M |
| Change % |
-0.10% |
| Net Change |
▼ -0.0400 |
| Insider Ownership |
0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2023 |
| Country | Canada |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-240,683.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-08-14 |
Sale |
-5000.00 |
Smith Sean Michael |